Urea Kinetics in Patients on Regular Dialysis Treatment before and after Treatment with Recombinant Human Erythropoietin

Twenty -two continuous ambulatory peritoneal dialysis (CAPD) patients, mean age 48 years, at 3 U.K. renal units were assessed with the Nottingham Health Profile (N HP) before and after treatment with recombinant human erythropoietin (r-HuEPO). Mean (SD) hemoglobin (Hb) at baseline was 7.5 (1.0) gIn/dl and 10.8 (1.5) gIn/dl at retest. There were significant improvements in energy (p<0.0001), social life (p<0.005), relationships at home (p<0.05) and leisure pursuits (p<0.05). Twelve patients, mean age 51 years, who had already completed more than 9 months on r-HuEPO treatment were reassessed to determine the changes sustained. Mean (SD) Hb at second retest was 12.8 (1.3) gm/dl. Improvement in energy continued to be significant, and emotional wellbeing showed further improvement. Problems with household tasks, which had not shown significant improvement at Test B, were now considerably reduced (p=0.016). The study showed far-reaching benefits similar to those reported in hemodialysis patients, in a population with a higher mean age and higher potential coexisting illness or disability than most reported hemodialysis studies.

Download Full-text

The effects of corticotropin and growth hormone releasing hormones on their respective secretory axes in chronic hemodialysis patients before and after correction of anemia with recombinant human erythropoietin

The Journal of Clinical Endocrinology & Metabolism ◽

10.1210/jc.78.1.63 ◽

1994 ◽

Vol 78 (1) ◽

pp. 63-69 ◽

Cited By ~ 6

Author(s):

G. Ramirez

Keyword(s):

Growth Hormone ◽

Recombinant Human Erythropoietin ◽

Hemodialysis Patients ◽

Chronic Hemodialysis ◽

Human Erythropoietin ◽

Before And After

Download Full-text

Autonomic Neuropathy in Hemodialysis Patients Treated with Recombinant Human Erythropoietin

The International Journal of Artificial Organs ◽

10.1177/039139889601901003 ◽

1996 ◽

Vol 19 (10) ◽

pp. 574-577 ◽

Cited By ~ 3

Author(s):

O.O. Stojcheva-Taneva ◽

M.H. Polenakovic

Keyword(s):

Blood Pressure ◽

Autonomic Dysfunction ◽

Recombinant Human Erythropoietin ◽

Hemodialysis Patients ◽

Maintenance Hemodialysis ◽

Exercise Heart Rate ◽

Control Group ◽

Human Erythropoietin ◽

Group I ◽

Before And After

Autonomic nervous system (ANS) function was evaluated in hemodialysis patients treated with recombinant human erythropoietin (rHu-EPO) before and after therapy, in an effort to evaluate the role of anemia in the genesis of autonomic dysfunction in chronic renal failure (CRF). Studies were conducted using a battery of five cardiovascular reflex tests: Valsalva maneuver, handgrip exercise, heart rate response to standing (30:15 index), post-Valsalva rise in blood pressure and postural drop in blood pressure. The patients were divided into two groups: group I consisted of 14 patients on maintenance hemodialysis treated with rHu-EPO for one year, and group II - 13 hemodialysis patients treated with rHu-EPO for two years. The results of the tests were compared before and after the correction of anemia by rHu-EPO in each group, as well as with the control group of ten healthy subjects. Data show that renal anemia is not implicated in the genesis of ANS dysfunction in hemodialysis patients, since correction of same by rHu-EPO does not improve the autonomic dysfunction.

Download Full-text

Intraperitoneal Recombinant Human Erythropoietin Therapy: Influence of the Duration of Continuous Ambulatory Peritoneal Dialysis Treatment and Peritonitis

American Journal of Nephrology ◽

10.1159/000168855 ◽

1995 ◽

Vol 15 (4) ◽

pp. 312-317 ◽

Cited By ~ 2

Author(s):

Tung-Po Huang ◽

Ching-Yuang Lin

Keyword(s):

Peritoneal Dialysis ◽

Continuous Ambulatory Peritoneal Dialysis ◽

Recombinant Human Erythropoietin ◽

Dialysis Treatment ◽

Human Erythropoietin

Download Full-text

Hematocrit Influence on Peritoneal Dialysis Effectiveness during Recombinant Human Erythropoietin Treatment in Patients with Chronic Renal Failure

Peritoneal Dialysis International ◽

10.1177/089686089301302s134 ◽

1993 ◽

Vol 13 (2_suppl) ◽

pp. 550-552 ◽

Cited By ~ 3

Author(s):

Andrzej Ksiazek ◽

Elzbieta Baranowska-Daca

Keyword(s):

Peritoneal Dialysis ◽

Recombinant Human Erythropoietin ◽

Glucose Absorption ◽

Mean Value ◽

Protein Loss ◽

Peritoneal Equilibration Test ◽

Sodium Potassium ◽

Human Erythropoietin ◽

Before And After ◽

Erythropoietin Treatment

Seven intermittent peritoneal dialysis (IPD) patients were investigated before and after correction of anemia with recombinant human erythropoietin (r-HuEPO). When hematocrit exceeded 300/0, the peritoneal equilibration test was performed at 1, 2, 4, 8 hours. Correction of anemia was associated with a mean value Increment In creatinine and phosphate clearance In 1 and 2-hour dwells. Differences In clearance of sodium, potassium, and urea In protein loss and glucose absorption before and after r-HuEPO therapy were not statistically significant. Increased creatinine and phosphate clearance during short dwells can be effected in IPD patients.

Download Full-text

Injections of recombinant human erythropoietin increases lactate influx into erythrocytes

Journal of Applied Physiology ◽

10.1152/japplphysiol.00715.2003 ◽

2004 ◽

Vol 97 (1) ◽

pp. 326-332 ◽

Cited By ~ 14

Author(s):

Philippe Connes ◽

Corinne Caillaud ◽

Jacques Mercier ◽

Didier Bouix ◽

Jean François Casties

Keyword(s):

Placebo Group ◽

Recombinant Human Erythropoietin ◽

Lactate Concentration ◽

Band 3 ◽

Monocarboxylate Transporter ◽

Maximal Velocity ◽

Lactate Transport ◽

Human Erythropoietin ◽

Before And After ◽

Lactate Uptake

Previous studies showed that erythropoietin not only increases erythrocyte production but is also essential in both the synthesis and the good functioning of several erythrocyte membrane proteins, including band 3. It is still unknown whether anion and/or H+ fluxes are modified by erythropoietin. This study aimed to evaluate the effect of recombinant human erythropoietin (rHuEPO) injections on lactate transport into erythrocytes via band 3 and H+-monocarboxylate transporter MCT-1, two proteins involved in lactate exchange. Nine athletes received subcutaneous rHuEPO (50 U/kg body mass 3 times a week for 4 wk), and seven athletes received a saline solution (placebo group). All subjects were also supplemented with oral iron and vitamins B9 and B12. Lactate transport into erythrocytes was studied before and after the rHuEPO treatment at different lactate concentrations (1.6, 8.1, 41, and 81.1 mM). After treatment, MCT-1 lactate uptake was increased at 1.6, 41 ( P < 0.01), and 81.1 mM lactate concentration ( P < 0.001) although lactate uptake via band 3 and nonionic diffusion were unchanged. MCT-1 maximal velocity increased in the rHuEPO group ( P < 0.05), reaching higher values than in the placebo group ( P < 0.05) after treatment. Our results show that rHuEPO injections increased MCT-1 lactate influx at low and high lactate concentrations. The increase in MCT-1 maximal velocity suggests that rHuEPO may stimulate MCT-1 synthesis during erythrocyte formation in bone marrow.

Download Full-text